Venetoclax

Venetoclax in the glossary for Waldenström's macroglobulinemia

A small molecule BCL2 inhibitor

Venetoclax (ABT-199) is a novel, orally bioavailable small-molecule inhibitor for selective targeting of B-cell lymphoma 2 (BCL2). Venetoclax is in clinical development and shows high efficacy and safety in particular in the treatment of chronic lymphocytic leukemia (CLL), but preliminarily also in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) Venetoclax.¹ Venetoclax in combination with a hypomethylating agent is approved by the European Commission (EC) for patients with newly diagnosed acute myeloid leukemia (AML) who are ineligible for intensive chemotherapy as well as in patients with AML, in combination with either azacitidine or decitabinein in adults who cannot have intensive chemotherapy. In Australia, Venetoclax in combination with obinutuzumab is indicated for the treatment of newly diagnosed patients with Acute Myeloid Leukaemia (AML) who are ineligible for intensive chemotherapy.²

Glossary overview

References

1.SmPC Venetoclax. Available from; https://www.ema.europa.eu/en/documents/product-information/venclyxto-epar-product-information_en.pdf. Accessed November 12th, 2021.

2.Australian Public Assessment Report for Venetoclax. Available from; https://www.tga.gov.au/auspar/auspar-venetoclax-1. Accessed November 12th, 2021.

This website contains information for a broad scientific audience and may include information on products or indications that are not licensed, approved, or accessible in your country or region. Prescribing information or other medical information for products may also differ between countries or regions. Please consult the appropriate national or regional regulatory authority for specific information on a product or indication included here.